CompanyGraph
Sectra AB
SECT.B · Nasdaq Stockholm · Sweden
Price data from its 0A0L listing on LSE
sectra.comFinancials as of FY2026
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $6.16B, above the global median of $1.15B
- PositionGross margin is 87.8%, higher than 95% of its Medical Devices peers (median 61%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Trailing P/E
141.31xvs Medical Devices peers
Revenue (TTM)
2.52BSEK265.31M · vs all stocks (USD)
Profit Margin
15.20%vs Medical Devices peers
Beta
1.22xvs all stocks
52-Week Change
-21.73%vs all stocks
Enterprise Value
22.73BSEK2.40B · vs all stocks (USD)
Trailing P/E
141.31xvs Medical Devices peers
Forward P/E
83.69xvs Medical Devices peers
PEG Ratio
6.86xvs Medical Devices peers
Price to Sales (TTM)
22.89xvs Medical Devices peers
Price to Book (MRQ)
39.08xvs Medical Devices peers
Enterprise to Revenue
9.04xvs Medical Devices peers
Enterprise to EBITDA
46.19xvs Medical Devices peers
Gross Margin
87.78%vs Medical Devices peers
Profit Margin
15.20%vs Medical Devices peers
Operating Margin
18.31%vs Medical Devices peers
Return on Assets (TTM)
11.95%vs Medical Devices peers
Return on Equity (TTM)
30.20%vs Medical Devices peers
Revenue (TTM)
2.52BSEK265.31M · vs all stocks (USD)
Revenue per Share (TTM)
13.05SEKUpdated Jul 14, 2026Quarterly Revenue Growth
22.00%vs Medical Devices peers
Gross Profit (TTM)
1.00BSEK105.62M · vs all stocks (USD)
EBITDA (TTM)
832.48MSEK87.82M · vs all stocks (USD)
Net Income (TTM)
382.38MSEK40.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.70%vs Medical Devices peers
Operating Cash Flow (TTM)
406.32MSEK42.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
160.82MSEK16.97M · vs all stocks (USD)
Payout Ratio
50.25%vs Medical Devices peers
Minority Interest (Equity)
2.81MSEKFY2026 · Apr 30, 2026Revenue
3.55BSEKFY2026 · Apr 30, 2026Cost of Goods Sold
403.75MSEKFY2026 · Apr 30, 2026Gross Profit
3.14BSEKFY2026 · Apr 30, 2026Operating Income
716.63MSEK75.60M · vs all stocks (USD)
Pre-tax Income
728.95MSEKFY2026 · Apr 30, 2026Income Tax Expense
165.17MSEKFY2026 · Apr 30, 2026Net Income
563.78MSEKFY2026 · Apr 30, 2026EBIT
736.47MSEKFY2026 · Apr 30, 2026EBITDA (Income Statement)
858.31MSEKFY2026 · Apr 30, 2026Other Operating Expenses
586.49MSEKFY2026 · Apr 30, 2026Non-operating Interest Income
28.02MSEKFY2026 · Apr 30, 2026Non-operating Interest Expense
7.52MSEKFY2026 · Apr 30, 2026EPS (Basic)
2.93SEKFY2026 · Apr 30, 2026EPS (Diluted)
2.93SEKFY2026 · Apr 30, 2026Basic Shares Outstanding
192.67MSharesFY2026 · Apr 30, 2026Diluted Shares Outstanding
192.67MSharesFY2026 · Apr 30, 2026Net Income from Continuing Operations
710.63MSEKFY2026 · Apr 30, 2026Minority Interests (P&L)
0.00SEKFY2026 · Apr 30, 2026Preferred Stock Dividends
0.00SEKFY2026 · Apr 30, 2026Operating Cash Flow
1.07BSEKFY2026 · Apr 30, 2026Free Cash Flow
980.31MSEKFY2026 · Apr 30, 2026Cash & Cash Equivalents (End of Period)
1.81BSEKFY2026 · Apr 30, 2026Starting Profit (CF Statement)
710.63MSEKFY2026 · Apr 30, 2026Change in Accounts Receivable (CF)
-161.04MSEKFY2026 · Apr 30, 2026Change in Other Assets/Liabilities
516.21MSEKFY2026 · Apr 30, 2026Capital Expenditures
-85.49MSEKFY2026 · Apr 30, 2026Net Intangibles (CF)
-103.11MSEKFY2026 · Apr 30, 2026Net Acquisitions
-18.86MSEKFY2026 · Apr 30, 2026Purchase of Investments
0.00SEKFY2026 · Apr 30, 2026Net Investing Cash Flow
-104.35MSEKFY2026 · Apr 30, 2026Common Stock Repurchase
-404.60MSEKFY2026 · Apr 30, 2026Net Financing Cash Flow
-401.79MSEKFY2026 · Apr 30, 2026Shares Outstanding
192.67MSharesUpdated Jul 14, 2026Float Shares
128.49MSharesUpdated Jul 14, 2026Total Cash (MRQ)
808.21MSEK85.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.20SEKUpdated Jul 14, 2026Total Debt (MRQ)
78.00MSEK8.23M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0563xvs Medical Devices peers
Current Ratio (MRQ)
1.72xvs Medical Devices peers
Book Value per Share (MRQ)
7.20SEKUpdated Jul 14, 2026Total Assets
4.47BSEK471.93M · vs all stocks (USD)
Total Current Assets
3.56BSEKFY2026 · Apr 30, 2026Total Liabilities
2.34BSEKFY2026 · Apr 30, 2026Total Non-current Assets
913.98MSEKFY2026 · Apr 30, 2026Total Non-current Liabilities
124.01MSEKFY2026 · Apr 30, 2026Total Current Liabilities
2.21BSEKFY2026 · Apr 30, 2026Cash
1.81BSEKFY2026 · Apr 30, 2026Cash & Cash Equivalents
1.81BSEKFY2026 · Apr 30, 2026Accounts Receivable
722.32MSEKFY2026 · Apr 30, 2026Inventory
42.51MSEKFY2026 · Apr 30, 2026Accounts Payable
183.80MSEKFY2026 · Apr 30, 2026Short-term Debt
20.98MSEKFY2026 · Apr 30, 2026Other Current Liabilities
17.38MSEKFY2026 · Apr 30, 2026Long-term Debt
55.51MSEKFY2026 · Apr 30, 2026Common Stock (Book)
39.02MSEKFY2026 · Apr 30, 2026Retained Earnings
1.63BSEKFY2026 · Apr 30, 2026Total Shareholders' Equity
2.14BSEK225.58M · vs all stocks (USD)
52-Week Change
-21.73%vs all stocks
Beta
1.22xvs all stocks
50-Day MA
279.10SEKUpdated Jul 14, 2026200-Day MA
256.79SEKUpdated Jul 14, 2026Avg 10-Day Volume
6.58KSharesUpdated Jul 14, 2026Avg 30-Day Volume
12.11KSharesUpdated Jul 14, 2026Diluted EPS (TTM)
1.99SEKUpdated Jul 14, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 87.8%, higher than 95% of its Medical Devices peers (median 61%)Significant
Gross margin: 0.88Industry median: 0.61Industry P95: 0.85Peers compared: 102
Return on equity is 30.2%, higher than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: 0.30Industry median: 0.03Industry P95: 0.17Peers compared: 102
Return on assets is 12%, higher than 95% of its Medical Devices peers (median 1.9%)Significant
Return on assets: 0.12Industry median: 0.02Industry P95: 0.12Peers compared: 102
Price-to-book is 39.08×, higher than 95% of its Medical Devices peers (median 2.69×)Significant
Price-to-book: 39.08Industry median: 2.69Industry P95: 16.17Peers compared: 102
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.91
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $6.16B, above the global median of $1.15BNotable
Market cap (USD): 6,161,163,465.145Global Median: 1,146,734,693.424
Levered free cash flow is $16.97M, above the global median of $16.24MNotable
Levered free cash flow (USD): 16,965,244.432Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Ligand Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunshine Guojian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
H. Lundbeck A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Getinge AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Games Workshop Group PLC
11 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
NVIDIA Corporation
11 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin